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Objective: Demonstrate the feasibility and effectiveness of tricuspid VIV implantation.
Methods: Four patients underwent VIV implantation. Underlying diagnoses were: Ebstein anomaly n = 2, Carcinoid syndrome n = 1 and previously replaced native valve for infective endocarditis n = 1. Previous valve type and size was: Biocor (St Jude Medical), n = 2 (27 mm, 33 mm), Perimount n = 1 (29 mm) and Medtronic Intact n = 1 (33 mm). Valve dysfunction was regurgitation in 3 and stenosis in 1. Procedural access was via the femoral vein in 3 and jugular vein in 1. Edwards Sapien S3 valves (29 mm n = 3 and 26 mm n = 1) were deployed and all procedures were successful and uncomplicated.
Results: None or trivial residual tricuspid regurgitation was present in all cases and median post procedural tricuspid valve mean gradient was 4mmHg (range 2-5). Median follow-up was 13.5 months (range 2-17) and median gradient was 6mmHg. One patient has developed progressive severe stenosis (MG 14mmHg) despite anticoagulation.
Conclusion: All four patients underwent successful tricuspid VIV implantation for severely degenerated (regurgitant or stenotic) tricuspid surgical bioprostheses. Both the transjugular and femoral approach may be used successfully, with unique clinical advantages for each depending on the surgical valve orientation. Tricuspid VIV implantation is clinically feasible with excellent acute haemodynamic outcomes and safety.
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Patients with Aortic Stenosis Exhibit Early Improved Endothelial Function Following Aortic Valve Replacement
A. Comella 1, * , M. Michail 2 , A. Ihydayhid 2 , M. Baldi 3 , J. Cameron 1,2,3 , A. Brown 1,2 Background: Patients with severe aortic stenosis (AS) have impaired coronary flow reserve (CFR), resulting in myocardial ischaemia in absence of obstructive coronary disease. Endothelial dysfunction (ED) contributes towards impaired CFR in patients with AS, although it remains unknown whether endothelial function recovers following valve replacement. It is also unclear whether any hypothesised improvement immediately as consequence of arterial haemodynamics or more long-term.
Methods: Patients with severe AS undergoing transcatheter and surgical valve replacement had assessment of endothelial-independent and -dependent flow mediated dilation (FMD) via ultrasound and EndoPAT2000. Measurements were performed prior to, 24 hrs and 28 days after valve replacement. Intraobserver FMD reproducibility was excellent (intraclass correlation coefficient 0.96).
Results: To date, 8 out of 40 patients have been recruited into the trial (75% male). Seven (87.5%) patients underwent transcatheter valve replacement. FMD was successfully performed in all patients pre-and immediately post-procedure, while EndoPAT measurements were possible in 75% of patients. FMD significantly increased from 5.8% (pre-) to 11.6% post-procedure (p = 0.01). Although a similar trend was observed for EndoPAT measures (pre-2.00 vs. post-2.36), this did not reach statistical significance (p > 0.05). FMD follow-up data at 28 days was available for 2 patients and demonstrated that the improvement was sustained (8.5%). We anticipate complete data will be available by time of presentation.
Conclusion: Our preliminary data shows that endothelial function in patients with AS improves quickly after valve replacement, likely as a result of improved arterial haemodynamics. This improvement may result in restoration of CFR and alleviate myocardial ischaemia.
Background: Outcomes after out-of-hospital cardiac arrest (OHCA) remain poor, and percutaneous coronary intervention (PCI) may have prognostic benefit in patients with a culprit coronary lesion. We aimed to describe outcomes among patients undergoing PCI following OHCA and the effect of ST-elevation myocardial infarction on outcome.
Methods: Data were prospectively collected on 1,047 consecutive PCI procedures following OHCA at six Victorian public hospitals from 2005 to 2017. Patients were divided into those with STEMI (OHCA-S) and those without (OHCA-NS). Outcomes were compared against patients with STEMI only without OHCA (n = 9,694).
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Sir Charles Gairdner Hospital, Nedlands, Australia
Objectives: Severe symptomatic mitral regurgitation (MR) is associated with significant morbidity and mortality without treatment. Percutaneous edge-to-edge repair of severe MR with MitraClip has emerged as an alternative to surgical treatment for high risk or inoperable patients. This study aimed to describe our experience of MitraClip implantation in Western Australia over the past seven years.
Methods: Data of patients who underwent MitraClip implantation at Sir Charles Gairdner Hospital between January 2011 and December 2017 were retrospectively collected and analysed.
Results: Ninety-five high-risk consecutive patients with severe MR (grade 3+ or more) underwent MitraClip implantation (mean age 77.5 ± 10.1 years). Mean Society of Thoracic Surgeons (STS) mortality score was 7.98% (33.7% of patients had STS score ≥8%) and 96.8% of patients were in New York Heart Association (NYHA) class III or IV. Pre-procedural mean left ventricular ejection fraction was 45.1% ± 17.2%. Device implantation was successful in ninety-four patients (98.9%). There were no acute deaths or myocardial infarctions. One patient (1.1%) suffered a post-procedural stroke without permanent neurological deficits. Median post-procedural length of stay was 2 days, with 82 (86.3%) patients being discharged home. Actuarial survival was 100%, 97.9% and 88.4% at 30 days, 90 days and 1 year respectively. At 12 months, 81.1% of survivors were NYHA class II or less.
Conclusions: At our centre, MitraClip implantation was carried out with high procedural success and low complication rates. There was successful post-procedural reduction of MR severity and sustained improvements in NYHA class at 12 months. Methods: A retrospective audit was performed for consecutive patients who underwent pericardiocentesis at Liverpool hospital from February 2018-January 2019 using the hospital electronic medical record.
Results: 34 patients required drainage of pericardial effusions. Mean age was 60.8 ± 19.4 years (55% male). 25/34 (74%) were performed percutaneously by Cardiology with Cardiology AT performing the majority of cases (17/25). All were echocardiographic-assisted. 47% were performed after-hours. Mean effusion-maximal diameter was 2.77 cm ± 1.02 cm. 85% had echocardiographic features of tamponade and 71% had clinical features of tamponade. 13 (37%)were malignant, 9 (25%) iatrogenic (44% postcardiothoracic surgery) and 4 (11%) were inflammatory. 11% took aspirin,17% DAPT and 26% were anticoagulated. Most common approach was subcostal (68%). Mean total drainage output was 770.8 ± 460 ml, average dwell time 54.7 h ± 31.4 h. 4/25 had fluid re-accumulation managed with surgical pericardial window. Complications occurred in 2/25 cases [1 RV needle perforation successfully surgical repaired, 1 death from cardiac arrest from pacing wire perforation]. 9/34 (26%) had initial surgical management and were more likely to be loculated and posterior or post-surgical with suspected clot tamponade. There was 1 failed drainage and 1 death in the surgical group. Surgical management was associated with an increased ICU-stay (mean 2.7 ± 4.5 days) compared to nonsurgical (0 days).
Conclusion: Percutaneous pericardiocentesis is a successful approach to draining pericardial effusions. Complications are rare and commonly successfully surgically managed. http://dx.doi.org/10.1016/j.hlc.2019.06.667
